Nuvectis Pharma(NVCT) - 2025 Q2 - Quarterly Report

Financial Performance - The company has incurred losses since inception and has not generated any revenue, expecting continued losses for the foreseeable future[11]. - The company does not intend to pay dividends on its common stock in the foreseeable future, limiting returns to stock value appreciation[17]. Product Development and Regulatory Risks - The company is substantially dependent on the success of its product candidates, NXP900 and NXP800[11]. - The development and commercialization of pharmaceutical products are subject to extensive regulation, and the company may not obtain necessary regulatory approvals for its product candidates[11]. - Clinical trials are expensive and time-consuming, with uncertain outcomes that may not predict future results[11]. - If the company fails to demonstrate safety and efficacy for its product candidates, it may need to terminate development programs, harming its reputation[11]. Operational Needs - The company currently has 13 full-time employees and will need to grow its organization to meet operational goals[17]. - The company requires substantial additional capital to finance operations and achieve its goals, with potential delays in research or product development if capital is not raised[11]. Market and External Risks - Tariffs and trade measures could adversely affect the company's business and financial position[11]. - The company faces risks related to the manufacturing of its product candidates, which may encounter difficulties or interruptions[14].